

**JOINT STOCK COMPANY
DANANG PHARMACEUTICAL –
MEDICAL EQUIPMENT**

No.: 363/TB-CT

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Da Nang, March 27, 2026

“Re: Explanation of fluctuations in profit
after corporate income tax based on the
audited financial statements for 2025.”

**To: - State Securities Commission of Vietnam;
- Hanoi Stock Exchange.**

**1. Company name: Danang Pharmaceutical – Medical Equipment Joint Stock
Company**

2. Stock code: DDN (Upcom)

3. Head office: 02 Phan Dinh Phung, Hai Chau Ward, Danang City

4. Telephone: 0236.3822247

Fax: 0236.3891752

Published information content:

Pursuant to Circular No. 96/2020/TT-BTC dated November 16, 2020, Danang Pharmaceutical – Medical Equipment Joint Stock Company hereby provides the following explanation:

The profit after corporate income tax in the audited financial statements for 2025 has changed by 10% or more compared to the same period of the previous year:

Indicator	2025 Audited Financial Statements	2025 Audited Financial Statements	Difference (%)
Full-year profit after corporate income tax	4.085.916.083 đ	7.624.152.377 đ	-46%

Details:

Profit after corporate income tax in 2025 decreased by 46% compared to 2024, mainly due to the Company recognizing income from the disposal of unused accounts in 2024, while in 2025 the Company recorded a loss from its investment in the NeoVita Vaccination Center and Medical Services System in Ho Chi Minh City.

Recipients:

- As above;
- Company website;
- Filed at Office.

DEPUTY GENERAL DIRECTOR 



NGUYEN TRUNG